Autopsy report · NCT00005787
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
Cause of deathSlow enrollment, also staffing, sites or logistics
“Per PI due to poor/inadequate accrual.”
Life of this trial
- Registered 9 months after it had already started.
- Ran for about 2 years 4 months before it stopped.
- 3 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Conditions
- Lymphoma; Neutropenia
- Interventions
- epoetin alfa; filgrastim; recombinant flt3 ligand; recombinant interleukin-3; sargramostim; in vitro-treated peripheral blood stem cell transplantation
- Participants
- 3
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity
“PI decision due to under accrual.” - Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
“Due to poor accrual” - Pudendal vs Caudal Block for Pediatric Penile Surgery
“Lack of funding and change of PI” - Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
“Study closed by PI due to lower than expected accrual.” - A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
“Poor accrual rate”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.